ARGX:NSD-argenx NV ADR (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 629.99

Change

0.00 (0.00)%

Market Cap

USD 36.54B

Volume

0.15M

Analyst Target

USD 254.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 84.94B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.66B
BGNE BeiGene Ltd

N/A

USD 20.24B
UTHR United Therapeutics Corporatio..

N/A

USD 16.18B
MRNA Moderna Inc

N/A

USD 16.10B
RPRX Royalty Pharma Plc

N/A

USD 15.27B
SMMT Summit Therapeutics PLC

N/A

USD 13.67B
INCY Incyte Corporation

N/A

USD 13.52B
INSM Insmed Inc

N/A

USD 13.20B

ETFs Containing ARGX

FBT:LSE First Trust Global Funds .. 4.05 % 0.00 %

N/A

USD 8.11M
FBTU:LSE First Trust Global Funds .. 4.05 % 0.00 %

N/A

USD 8.11M
SRHE:XETRA Amundi Index Solutions - .. 3.20 % 0.00 %

N/A

USD 0.19B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.08 % 0.00 %

N/A

USD 0.02B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.64 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.64 % 0.00 %

N/A

N/A
2B78:XETRA iShares Healthcare Innova.. 2.48 % 0.00 %

N/A

USD 1.14B
DXSE:XETRA Xtrackers - Stoxx Europe .. 2.44 % 0.00 %

N/A

USD 0.14B
HEAL:SW iShares Healthcare Innova.. 2.39 % 0.00 %

N/A

N/A
ESIH:LSE iShares MSCI Europe Healt.. 2.33 % 0.00 %

N/A

USD 0.54B
STWX:SW SPDR® MSCI Europe Health.. 2.22 % 0.00 %

N/A

USD 0.67B
STW:PA SPDR® MSCI Europe Health.. 2.22 % 0.00 %

N/A

USD 0.68B
SPYH:XETRA SPDR® MSCI Europe Health.. 2.22 % 0.00 %

N/A

USD 0.66B
XSDR:LSE Xtrackers MSCI Europe Hea.. 2.21 % 0.00 %

N/A

USD 0.22B
2B70:XETRA iShares Nasdaq US Biotech.. 2.16 % 0.00 %

N/A

USD 0.52B
EXV4:XETRA iShares STOXX Europe 600 .. 2.10 % 0.00 %

N/A

USD 0.70B
SXDPEX:SW iShares STOXX Europe 600 .. 2.10 % 0.00 %

N/A

USD 0.44B
IBBQ Invesco Nasdaq Biotechnol.. 2.03 % 0.00 %

N/A

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 2.02 % 0.00 %

N/A

USD 0.52B
V3ET:F VanEck Vectors ETFs N.V. .. 1.67 % 0.00 %

N/A

USD 0.05B
V3ET:XETRA VanEck Sustainable Europe.. 1.67 % 0.00 %

N/A

USD 0.05B
TEET:LSE VanEck Sustainable Europe.. 1.65 % 0.00 %

N/A

USD 0.05B
TEET:SW 1.36 % 0.00 %

N/A

N/A
TEGB:LSE VanEck Sustainable Europe.. 1.25 % 0.00 %

N/A

N/A
2B77:XETRA iShares Ageing Population.. 0.82 % 0.00 %

N/A

USD 0.50B
TSWE:F VanEck Sustainable World .. 0.64 % 0.00 %

N/A

USD 0.72B
TSWE:XETRA VanEck Sustainable World .. 0.64 % 0.00 %

N/A

USD 0.72B
TSGB:LSE VanEck Sustainable World .. 0.64 % 0.00 %

N/A

USD 0.82B
TSWE:SW VanEck Sustainable World .. 0.62 % 0.00 %

N/A

USD 0.82B
AGED:SW iShares Ageing Population.. 0.61 % 0.00 %

N/A

N/A
TSWE:LSE VanEck Sustainable World .. 0.49 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.42B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.08B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HLTH:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

N/A
DXSE:F Xtrackers Stoxx Europe 60.. 0.00 % 0.00 %

N/A

N/A
EXV4:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
SPYH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

N/A

USD 4.16M
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
ESIH:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

USD 0.51B
ESIH:XETRA iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

USD 0.60B
HEAE:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 65.90% 87% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.90% 87% B+ 89% A-
Trailing 12 Months  
Capital Gain 63.10% 86% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.10% 86% B+ 89% A-
Trailing 5 Years  
Capital Gain 291.78% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 291.78% 95% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 25.99% 68% D+ 78% C+
Dividend Return 25.99% 68% D+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.34% 83% B 58% F
Risk Adjusted Return 80.37% 99% N/A 91% A-
Market Capitalization 36.54B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector